Literature DB >> 10646882

Search for NTRK1 proto-oncogene rearrangements in human thyroid tumours originated after therapeutic radiation.

A Bounacer1, M Schlumberger, R Wicker, J A Du-Villard, B Caillou, A Sarasin, H G Suárez.   

Abstract

Rearrangements of NTRK1 proto-oncogene were detected in 'spontaneous' papillary thyroid carcinomas with a frequency varying from 5 to 25% in different studies. These rearrangements result in the formation of chimaeric genes composed of the tyrosine kinase domain of NTRK1 fused to 5' sequences of different genes. To investigate if the NTRK1 gene plays a role in radiation-induced thyroid carcinogenesis, we looked for the presence of NTRK1-activating rearrangements in 32 human thyroid tumours (16 follicular adenomas, 14 papillary carcinomas and two lymph-node metastases of papillary thyroid carcinomas) from patients who had received external radiation, using the reverse transcription polymerase chain reaction, Southern blot and direct sequencing techniques. These data were compared with those obtained in a series of 28 'spontaneous' benign and malignant thyroid tumours, collected from patients without a history of radiation exposure and four in vitro culture cell lines derived from 'spontaneous' thyroid cancers. Our results concerning the radiation-associated tumours showed that only rearrangements between NTRK1 and TPM3 genes (TRK oncogene) were detected in 2/14 papillary carcinomas and in one lymph-node metastasis of one of these papillary thyroid carcinomas. All the radiation-associated adenomas were negative. In the 'spontaneous' tumours, only one of the 14 papillary carcinomas and one of the four in vitro culture cell lines, derived from a papillary carcinoma, presented a NTRK1 rearrangement also with the TPM3 gene. Twenty-five of this series of radiation-associated tumours were previously studied for the ras and RET/PTC oncogenes. In conclusion, our data: (a) show that the overall frequency of NTRK1 rearrangements is similar between radiation-associated (2/31: 6%) and 'spontaneous' epithelial thyroid tumours (2/32: 6%). The frequency, if we consider exclusively the papillary carcinomas, is in both cases 12%; (b) show that the TRK oncogene plays a role in the development of a minority of radiation-associated papillary thyroid carcinomas but not in adenomas; and (c) confirm that RET/PTC rearrangements are the major genetic alteration associated with ionizing radiation-induced thyroid tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10646882      PMCID: PMC2363282          DOI: 10.1054/bjoc.1999.0920

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  38 in total

1.  Thyroid cancer after Chernobyl.

Authors:  V S Kazakov; E P Demidchik; L N Astakhova
Journal:  Nature       Date:  1992-09-03       Impact factor: 49.962

2.  The trk proto-oncogene product: a signal transducing receptor for nerve growth factor.

Authors:  D R Kaplan; B L Hempstead; D Martin-Zanca; M V Chao; L F Parada
Journal:  Science       Date:  1991-04-26       Impact factor: 47.728

3.  Presence of mutations in all three ras genes in human thyroid tumors.

Authors:  H G Suarez; J A du Villard; M Severino; B Caillou; M Schlumberger; M Tubiana; C Parmentier; R Monier
Journal:  Oncogene       Date:  1990-04       Impact factor: 9.867

4.  The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line.

Authors:  M Santoro; R M Melillo; M Grieco; M T Berlingieri; G Vecchio; A Fusco
Journal:  Cell Growth Differ       Date:  1993-02

5.  Radiation-associated and 'spontaneous' human thyroid carcinomas show a different pattern of ras oncogene mutation.

Authors:  P A Wright; E D Williams; N R Lemoine; D Wynford-Thomas
Journal:  Oncogene       Date:  1991-03       Impact factor: 9.867

6.  High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma.

Authors:  I Bongarzone; M A Pierotti; N Monzini; P Mondellini; G Manenti; R Donghi; S Pilotti; M Grieco; M Santoro; A Fusco
Journal:  Oncogene       Date:  1989-12       Impact factor: 9.867

7.  The trk proto-oncogene encodes a receptor for nerve growth factor.

Authors:  R Klein; S Q Jing; V Nanduri; E O'Rourke; M Barbacid
Journal:  Cell       Date:  1991-04-05       Impact factor: 41.582

8.  gsp mutations in human thyroid tumours.

Authors:  H G Suarez; J A du Villard; B Caillou; M Schlumberger; C Parmentier; R Monier
Journal:  Oncogene       Date:  1991-04       Impact factor: 9.867

9.  TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas.

Authors:  A Greco; M A Pierotti; I Bongarzone; S Pagliardini; C Lanzi; G Della Porta
Journal:  Oncogene       Date:  1992-02       Impact factor: 9.867

10.  Low frequency of rearrangements of the ret and trk proto-oncogenes in Japanese thyroid papillary carcinomas.

Authors:  W Wajjwalku; S Nakamura; Y Hasegawa; K Miyazaki; Y Satoh; H Funahashi; M Matsuyama; M Takahashi
Journal:  Jpn J Cancer Res       Date:  1992-07
View more
  8 in total

1.  (R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors.

Authors:  Ha-Soon Choi; Paul V Rucker; Zhicheng Wang; Yi Fan; Pamela Albaugh; Greg Chopiuk; Francois Gessier; Fangxian Sun; Francisco Adrian; Guoxun Liu; Tami Hood; Nanxin Li; Yong Jia; Jianwei Che; Susan McCormack; Allen Li; Jie Li; Auzon Steffy; AnneMarie Culazzo; Celine Tompkins; Van Phung; Andreas Kreusch; Min Lu; Bin Hu; Apurva Chaudhary; Mahavir Prashad; Tove Tuntland; Bo Liu; Jennifer Harris; H Martin Seidel; Jon Loren; Valentina Molteni
Journal:  ACS Med Chem Lett       Date:  2015-03-16       Impact factor: 4.345

2.  BAC-FISH assays delineate complex chromosomal rearrangements in a case of post-Chernobyl childhood thyroid cancer.

Authors:  Johnson Kwan; Adolf Baumgartner; Chun-Mei Lu; Mei Wang; Jingly F Weier; Horst F Zitzelsberger; Heinz-Ulrich G Weier
Journal:  Folia Histochem Cytobiol       Date:  2009       Impact factor: 1.698

3.  Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models.

Authors:  Pam Albaugh; Yi Fan; Yuan Mi; Fangxian Sun; Francisco Adrian; Nanxin Li; Yong Jia; Yelena Sarkisova; Andreas Kreusch; Tami Hood; Min Lu; Guoxun Liu; Shenlin Huang; Zuosheng Liu; Jon Loren; Tove Tuntland; Donald S Karanewsky; H Martin Seidel; Valentina Molteni
Journal:  ACS Med Chem Lett       Date:  2012-01-01       Impact factor: 4.345

4.  Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.

Authors:  James C H Yang; Marcia S Brose; Gilberto Castro; Edward S Kim; Ulrik N Lassen; Serge Leyvraz; Alberto Pappo; Fernando López-Ríos; John A Reeves; Marc Fellous; Frédérique Penault-Llorca; Erin R Rudzinski; Ghazaleh Tabatabai; Gilles Vassal; Alexander Drilon; Jonathan Trent
Journal:  BMC Cancer       Date:  2022-06-07       Impact factor: 4.638

5.  Kinase expression and chromosomal rearrangements in papillary thyroid cancer tissues: investigations at the molecular and microscopic levels.

Authors:  H-U G Weier; J Kwan; C-M Lu; Y Ito; M Wang; A Baumgartner; S W Hayward; J F Weier; H F Zitzelsberger
Journal:  J Physiol Pharmacol       Date:  2009-10       Impact factor: 3.011

6.  Delineating chromosomal breakpoints in radiation-induced papillary thyroid cancer.

Authors:  Heinz-Ulrich G Weier; Yuko Ito; Johnson Kwan; Jan Smida; Jingly F Weier; Ludwig Hieber; Chun-Mei Lu; Lars Lehmann; Mei Wang; Haig J Kassabian; Hui Zeng; Benjamin O'Brien
Journal:  Genes (Basel)       Date:  2011-09-01       Impact factor: 4.096

Review 7.  Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer.

Authors:  A Amatu; A Sartore-Bianchi; K Bencardino; E G Pizzutilo; F Tosi; S Siena
Journal:  Ann Oncol       Date:  2019-11-01       Impact factor: 51.769

8.  Thyroid cancer: molecular aspects and new therapeutic strategies.

Authors:  Enrique Grande; Juan José Díez; Carles Zafon; Jaume Capdevila
Journal:  J Thyroid Res       Date:  2012-07-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.